MARKET

BLUE

BLUE

Bluebird Bio Inc
NASDAQ
4.470
+0.210
+4.93%
After Hours: 4.480 +0.01 +0.23% 18:33 12/04 EST
OPEN
4.350
PREV CLOSE
4.260
HIGH
4.610
LOW
4.320
VOLUME
5.03M
TURNOVER
0
52 WEEK HIGH
8.58
52 WEEK LOW
2.520
MARKET CAP
488.73M
P/E (TTM)
-6.0032
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BLUE last week (1127-1201)?
Weekly Report · 15h ago
bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How
NASDAQ · 3d ago
bluebird bio Isn't Priced For Success
Bluebird bio is a clinical-stage biotechnology company developing gene therapies for severe genetic and rare diseases. Bluebird has had a rough run, down nearly 100% from its 2018 high and 49% in the past year. The downside risk for this stock is material, but the floor isn't $0. This is an asymmetric buy opportunity through december 20th.
Seeking Alpha · 4d ago
Biotech Stocks Facing FDA Decision In December 2023
NASDAQ · 4d ago
Buy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment
Bluebird bio specializes in gene therapies for severe genetic diseases and has two fda-approved products. The company has a pdufa date of december 20 for the approval of lovo-cel for sickle cell disease. Bluebird bio's cash runway is estimated to be at least 1.12 years.
Seeking Alpha · 5d ago
UP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers pack
Bluebird bio, bluebird bio and captivision among premarket gainers. Up fintech, cerence, irsa inversiones y representaciones, perf, tharimmune among the day's top premarket movers. Bluebirds bio, capt and crnc lead premarket gains in the biotechnology sector.
Seeking Alpha · 11/27 13:47
Weekly Report: what happened at BLUE last week (1120-1124)?
Weekly Report · 11/27 09:12
2 Biotech Stocks That Could Soar in December
NASDAQ · 11/26 21:44
More
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).

Webull offers bluebird bio Inc stock information, including NASDAQ: BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.